CJC-1295 with DAC Pharmacokinetics: Half-Life, Bioavailability, and Preclinical Data
Research Notice: This article covers research topics relevant to CJC-1295 with DAC — available from Palmetto Peptides for laboratory use only.
DISCLAIMER: This article is for educational and scientific research reference purposes only. All compounds discussed are not approved by the FDA for use in humans or animals. All data discussed here reflects preclinical animal research or laboratory use. Palmetto Peptides sells these compounds exclusively for in vitro and preclinical laboratory research. Nothing in this article constitutes medical advice.
CJC-1295 with DAC Pharmacokinetics: Half-Life, Bioavailability, and Preclinical Data
Last Updated: May 18, 2026 | Reading Time: Approximately 10 minutes | Author: Palmetto Peptides Research Team
Quick Answer
CJC-1295 with DAC exhibits a terminal plasma half-life of approximately 6 to 8 days in preclinical animal models — a pharmacokinetic profile that sets it apart from virtually all other GHRH analogs. Subcutaneous bioavailability in rodent models has been estimated at approximately 90% based on area-under-the-curve comparisons. A single administration in murine research subjects produces measurable growth hormone elevations lasting up to 7 days and IGF-1 elevations persisting for 9 to 11 days, enabling researchers to study sustained GHRH axis stimulation without daily compound administration.
Why Pharmacokinetics Matter for Growth Hormone Research
Pharmacokinetics — the study of how a compound moves through, is distributed within, and is eliminated from a biological system — determines how useful any research tool is in practice. For growth hormone axis research, pharmacokinetic parameters govern how often a compound must be administered to maintain relevant concentrations, what blood sampling windows are appropriate to capture the GH and IGF-1 response, and whether a compound is suitable for chronic studies versus acute endpoint measurements.
CJC-1295 with DAC's pharmacokinetic profile was the primary driver of its development. The ConjuChem research team that created it specifically aimed to design a GHRH analog with a half-life compatible with infrequent administration in clinical and preclinical applications — and the DAC technology delivered exactly that. Understanding the specific pharmacokinetic parameters is essential for any laboratory planning to use this compound in research protocols.
Terminal Half-Life: The Core Pharmacokinetic Parameter
The terminal half-life of CJC-1295 with DAC in preclinical models is consistently reported in the range of 6 to 8 days across multiple published studies. This value refers to the time it takes for plasma concentration of the compound to decrease by 50% during the elimination phase — after the distribution and albumin-binding reactions have reached equilibrium.
To put this in context with other GHRH-related compounds:
| Compound | Terminal Half-Life | GH Elevation Duration |
|---|---|---|
| Native GHRH | 2 to 7 minutes | Less than 30 minutes |
| Sermorelin (GHRH 1-29) | 10 to 20 minutes | Less than 2 hours |
| CJC-1295 without DAC (Mod GRF 1-29) | 20 to 30 minutes | 2 to 4 hours |
| CJC-1295 with DAC | 6 to 8 days | Up to 7 days |
The factor-of-roughly-1,000 improvement in half-life between native GHRH and CJC-1295 with DAC is entirely attributable to the albumin-binding DAC modification, which effectively converts the peptide's clearance pathway from rapid proteolysis and renal filtration to the slow, FcRn-mediated albumin recycling mechanism. For the underlying biochemical explanation, see our article on the CJC-1295 with DAC mechanism of action.
Absorption and Time to Peak Concentration
Following subcutaneous administration in rodent models, CJC-1295 with DAC is absorbed from the injection site and enters the systemic circulation. The time to maximum plasma concentration (Tmax) has been reported at approximately 1 to 2 hours in murine models. This relatively rapid absorption is consistent with the behavior of other subcutaneously administered peptides in the molecular weight range of CJC-1295 (approximately 3.3 kDa for the peptide portion, larger when bound to albumin).
During the absorption phase, the compound undergoes the albumin-conjugation reaction in circulation (a process that is largely complete within the first 1 to 2 hours after the peptide enters the bloodstream). Because the albumin-bound form is the dominant circulating species by the time blood sampling is typically performed, most pharmacokinetic measurements reflect the albumin-adduct concentration rather than free peptide.
Bioavailability: Subcutaneous vs. Intravenous Administration
Absolute bioavailability is determined by comparing the area under the plasma concentration-time curve (AUC) following subcutaneous administration to AUC following intravenous administration at the same dose. For CJC-1295 with DAC in rodent models, subcutaneous bioavailability has been estimated at approximately 90%, indicating highly efficient absorption from the subcutaneous depot with minimal first-pass loss.
This high subcutaneous bioavailability is consistent with what is observed for many peptide compounds of similar size and makes subcutaneous administration the practical standard for research protocols using this compound in animal models. Intramuscular administration has been used in some research contexts as well, with comparable bioavailability expected.
Volume of Distribution
The volume of distribution (Vd) describes how widely a compound distributes throughout the body relative to plasma. For CJC-1295 with DAC, the Vd in preclinical models is relatively constrained compared to highly lipophilic small molecules, consistent with a compound that is largely associated with circulating albumin. Albumin distributes primarily in plasma and interstitial fluid rather than intracellular compartments, so the effective Vd of the albumin-bound complex reflects this distribution pattern.
In practical terms, this means that CJC-1295 with DAC does not accumulate heavily in specific tissue compartments — its pharmacological action is mediated through circulating interaction with pituitary GHRHR as blood flows through the portal and systemic circulation, rather than through tissue depot accumulation.
GH Response Kinetics: Temporal Profile in Animal Models
The pharmacodynamic response to CJC-1295 with DAC — the actual GH secretory pattern in research subjects — has been characterized in multiple preclinical studies. The temporal profile is more complex than a simple peak-and-decline curve, because GH secretion is inherently pulsatile and CJC-1295 with DAC modulates the amplitude of those pulses rather than simply raising a flat GH baseline.
Acute GH Response (Hours 0 to 24)
In the first 24 hours following administration in murine models, a significant elevation in mean GH concentrations is typically observed. Because GH is measured in pulsatile samples, researchers typically report mean GH concentration over a sampling window rather than a single peak value. Studies using serial blood sampling in rodents have documented substantial mean GH increases in the first day following CJC-1295 with DAC administration.
Sustained Response (Days 1 to 7)
The GH elevating effect persists for days. Published data from Jetté and colleagues (2005) and Alba and colleagues (2006) demonstrated measurable GH elevations for up to 7 days in murine models following single-dose administration. The magnitude of elevation tends to be highest in the first 1 to 3 days and gradually declines as the circulating compound concentration falls during elimination.
IGF-1 Response Kinetics
Because IGF-1 is generated primarily in the liver in response to GH signaling, it lags behind the GH response by several hours. IGF-1 elevations typically peak later (often at 2 to 3 days post-administration in rodent studies) and persist longer than the GH elevation itself, with measurable IGF-1 increases documented for 9 to 11 days in some murine protocols. This extended IGF-1 response window is particularly valuable for researchers studying the downstream metabolic and anabolic effects of GH axis stimulation.
Metabolic Clearance and Elimination
The elimination of CJC-1295 with DAC is linked to the clearance of the albumin molecule to which it is covalently bound. Albumin clearance occurs primarily via cellular endocytosis followed by either lysosomal degradation or FcRn-mediated recycling back to circulation. Because the albumin-CJC-1295 adduct is a covalent complex, the peptide is degraded along with albumin in lysosomes rather than being cleaved or separated prior to albumin's cellular fate.
This means that the clearance rate of CJC-1295 with DAC approximates albumin's clearance rate — approximately 13 to 14 grams per day of albumin turnover in mammals, with a half-life of 19 days in humans and somewhat shorter in rodents (approximately 1.5 to 2 days in mice, though the compound's measured effective half-life of 6 to 8 days reflects the interplay between free and bound forms and the kinetics of the conjugation reaction).
Renal filtration plays a minimal role in elimination for the albumin-bound form, as albumin is too large to pass through the glomerular filtration barrier under normal physiological conditions. Any small residual fraction of free peptide that has not yet conjugated to albumin may be subject to some renal clearance, but this fraction is small given the rapid conjugation kinetics.
Pharmacokinetic Parameters Summary Table
| Parameter | Value in Preclinical Models | Notes |
|---|---|---|
| Terminal half-life (t½) | 6 to 8 days | Rodent and non-human primate models |
| Time to peak concentration (Tmax) | 1 to 2 hours | Subcutaneous administration in murine models |
| Subcutaneous bioavailability | ~90% | AUC comparison vs. IV |
| Duration of measurable GH elevation | Up to 7 days | Single-dose murine studies |
| Duration of measurable IGF-1 elevation | 9 to 11 days | Single-dose murine studies |
| Primary elimination pathway | Albumin-mediated lysosomal degradation | FcRn recycling protects from rapid clearance |
| Renal clearance contribution | Minimal for albumin-bound fraction | Albumin too large for glomerular filtration |
Species Differences in Pharmacokinetics
An important consideration for researchers is that pharmacokinetic parameters vary across species. The albumin half-life differs substantially between common laboratory animals and humans:
- Mice: Albumin half-life approximately 1.5 to 2 days; CJC-1295 with DAC effective half-life approximately 6 to 8 days
- Rats: Albumin half-life approximately 2.5 days; CJC-1295 with DAC effective half-life slightly longer than mice
- Non-human primates: Albumin half-life closer to human values (~15 days); CJC-1295 with DAC half-life accordingly longer
- Humans (Phase II data): Mean half-life of 5.8 to 8.1 days reported in the Phase II trial published by Teichman et al. (2006)
The longer half-life in humans compared to mice is consistent with the longer albumin half-life in humans. Researchers designing rodent studies should account for the fact that the relative duration of GH elevation may be shorter in mice (relative to the animal's lifespan and metabolic rate) than what would be expected in longer-lived species.
Implications for Dosing Frequency in Chronic Animal Studies
The 6 to 8 day half-life has direct implications for how researchers design chronic administration protocols in animal models. With a half-life in this range:
- Weekly administration produces relatively stable trough concentrations, with accumulation reaching approximate steady state by the third or fourth week of weekly dosing
- Bi-weekly administration (every two weeks) would result in more significant concentration troughs between doses but still maintain meaningful compound levels throughout the inter-dose interval
- At steady state with weekly dosing, peak-to-trough ratios are relatively moderate (roughly 2-fold), producing more consistent GH axis stimulation than would be achievable with shorter-acting GHRH analogs on any practical dosing schedule
This predictable accumulation behavior makes CJC-1295 with DAC well-suited to chronic rodent studies examining endpoints like body composition, bone density, or metabolic parameters over weeks to months. For more on the underlying research applications, see the complete guide to CJC-1295 with DAC research.
Pharmacokinetic Interactions with Other Research Compounds
When CJC-1295 with DAC is used in combination with other compounds in research protocols — particularly shorter-acting GHRP compounds like ipamorelin — the pharmacokinetics of each compound remain largely independent. Ipamorelin has a half-life of approximately 2 hours and produces acute GH pulses through ghrelin receptor activation. When administered alongside CJC-1295 with DAC (which provides sustained background GHRHR stimulation), the two compounds produce synergistic GH release without apparent pharmacokinetic interaction. See our article on CJC-1295 DAC and ipamorelin combination research for details on the pharmacodynamic interaction.
Albumin binding capacity is not typically a limiting factor even when multiple albumin-binding compounds are used simultaneously in research models, as albumin is present in large molar excess relative to the concentrations of research compounds used in preclinical studies.
Practical Pharmacokinetic Considerations for Laboratory Use
Researchers planning to use CJC-1295 with DAC should account for the following pharmacokinetic realities when designing protocols:
- Washout period: Due to the long half-life, a washout period of at least 4 to 5 weeks should be planned after the final administration before pharmacokinetic baseline conditions are re-established in animal subjects.
- Blood sampling timing: GH sampling immediately post-dose may not capture peak effects optimally; researchers typically sample at 6 to 24 hours post-dose for initial GH response and at multiple timepoints across the following week to characterize the duration of effect.
- IGF-1 measurement timing: Because IGF-1 lags behind GH, samples collected 48 to 72 hours post-administration often show the strongest IGF-1 elevations.
- Compound reconstitution: Proper preparation in bacteriostatic water ensures the compound is administered in a stable, active form. See our reconstitution and storage protocol for detailed guidance.
For laboratory procurement of research-grade CJC-1295 with DAC with verified pharmacokinetically relevant purity, Palmetto Peptides provides COA documentation with HPLC and MS verification. For guidance on interpreting COA data, see our article on CJC-1295 with DAC purity standards.
Frequently Asked Questions
What is the half-life of CJC-1295 with DAC in rodent models?
The terminal half-life of CJC-1295 with DAC in rodent models is approximately 6 to 8 days, based on published pharmacokinetic data from multiple preclinical studies. This is substantially longer than unmodified GHRH (2 to 7 minutes) or simpler GHRH analogs like sermorelin (10 to 20 minutes), and results from covalent albumin binding via the Drug Affinity Complex modification.
How long do GH elevations last after a single administration in animal models?
In murine research models, measurable GH elevations following a single administration of CJC-1295 with DAC have been documented for up to 7 days. IGF-1 elevations, which lag behind GH release due to hepatic processing time, have been observed for 9 to 11 days in some rodent study protocols.
What is the subcutaneous bioavailability of CJC-1295 with DAC?
Subcutaneous bioavailability of CJC-1295 with DAC in rodent models is estimated at approximately 90%, based on area-under-the-curve comparisons with intravenous administration. This high bioavailability makes subcutaneous administration the practical standard for preclinical research protocols.
Why does CJC-1295 with DAC have a longer half-life in humans than in mice?
Because its half-life is linked to albumin's clearance rate, and albumin itself has a longer half-life in humans (approximately 19 days) than in mice (approximately 1.5 to 2 days). In Phase II clinical trial data published by Teichman et al. (2006), the mean half-life of CJC-1295 with DAC in human subjects was 5.8 to 8.1 days — consistent with the proportion of the albumin half-life occupied in each species.
Does CJC-1295 with DAC accumulate with repeated administration in chronic studies?
Yes. With a half-life of 6 to 8 days, repeated weekly administration will result in compound accumulation until steady-state plasma concentrations are achieved, typically by the third or fourth week. Researchers should account for this accumulation when interpreting biological endpoints in chronic studies.
How does the pharmacokinetic profile of CJC-1295 with DAC affect blood sampling strategy?
Because GH and IGF-1 elevations persist for days, researchers must plan sampling across multiple timepoints rather than focusing solely on an acute peak. Optimal GH sampling windows are typically 6 to 24 hours post-administration, while IGF-1 is best captured at 48 to 72 hours and at multiple later timepoints through day 7 to 11.
Is there any renal elimination of CJC-1295 with DAC?
Renal clearance plays a minimal role for the albumin-bound fraction of CJC-1295 with DAC, as the albumin molecule is too large to pass through the normal glomerular filtration barrier. Any brief free-peptide fraction present before albumin conjugation is complete may undergo some renal filtration, but this represents a minor contribution to overall clearance.
Peer-Reviewed Citations
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1624
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology - Endocrinology and Metabolism. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
- Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone and IGF Research. 2009;19(6):471-477. doi:10.1016/j.ghir.2009.03.001
- Peters T Jr. All About Albumin: Biochemistry, Genetics, and Medical Applications. Academic Press; 1995. ISBN:978-0125521826
- Frohman LA, Jansson JO. Growth hormone-releasing hormone. Endocrine Reviews. 1986;7(3):223-253. doi:10.1210/edrv-7-3-223
Final Disclaimer: All compounds discussed are research chemicals not approved by the FDA for human or veterinary use. All content here is for scientific and educational reference only. Palmetto Peptides sells these products exclusively for in vitro and preclinical laboratory research.
Authored by the Palmetto Peptides Research Team | Last Updated: May 18, 2026